April 29, 2025
Pharmaceutical R&D runs on precision, but speed is what separates discovery from delivery. Across research workflows, every delay, whether in slide review, data handoff, or peer concordance, compounds downstream impact. This typically results in missed milestones, strained budgets, and lost momentum in programmes that can’t afford to wait.
With Patholytix, study acceleration is no longer a by-product. It is a design principle.
More than just a digital pathology platform, Patholytix is purpose-built to accelerate the entire research pathology lifecycle. From primary review to peer collaboration, scoring to archiving, and AI-enabled decision support, the platform enables fewer manual handovers, faster insights, and real-time readiness across sites, teams, and regulatory use cases.
For pathologists, that means more time spent on science, less on coordination. For study directors and sponsors, it means faster access to structured results without compromising review quality. And for R&D leadership, it means studies stay on track, with clearer visibility, fewer delays, and less downstream rework.
Having managed millions of whole slide images across some of the world’s largest pharmaceutical programmes, we’ve built Patholytix to reflect how research actually happens, and to remove the friction that slows it down.
The Real Reasons Studies Stall
Even in organisations that have embraced digital review, pathology workflows often remain fragmented. Scanned slides are managed in one tool, findings in another. Sponsors request annotations by email. Metadata is corrected in Excel. Peer review (which should be collaborative) becomes a relay race of uploads and delays.
For studies that span thousands of slides across multiple reviewers, these inefficiencies become material. Review cycles stretch from weeks to months. Consensus becomes harder to track. Compliance adds friction. With increasing study complexity in areas like translational models and biologics, the cost of slowness continues to rise.
Delays can also be introduced at the point of slide digitisation. Studies can stall before review even begins due to scanning backlogs, inconsistent metadata capture, or manual triage processes that separate scanned images from study context. And while AI tools show promise for prioritisation and lesion detection, most teams struggle to deploy them in a way that aligns with internal research protocols, GLP expectations, and sponsor-specific requirements. Without infrastructure that supports both automation and traceability, AI remains disconnected from routine study execution.
Patholytix: An IMS designed for velocity
Patholytix addresses these pain points head-on by delivering an integrated digital pathology ecosystem designed for speed. At its core are three capabilities that collectively redefine what acceleration means in practice.
Real-time collaboration without handoffs
Patholytix enables full web-based peer review, where reviewers can comment, annotate, and build consensus directly within the same interface. There are no downloads, no version confusion, and no email threads. Observations from peer reviewers are automatically visible to primaries, audit-logged, and linked to specific slide regions. Whether the reviewers are across the hall or across continents, the study can progress in real time.
Integrated scoring and regulatory-ready reporting
Unlike platforms that stop at image viewing, Patholytix incorporates dedicated modules for data capture, scoring, and regulatory output. Pathologists can record findings as they review, with structured metadata and tagging, and generate tables and reports directly within the platform. This eliminates duplication, reduces errors, and saves days (or weeks) per study. All data is stored in a traceable, audit-ready format, ensuring nothing is lost in translation.
This functionality extends beyond preclinical workflows. For clinical trial support, Patholytix provides full traceability of image assessments used in biomarker validation, patient stratification, and tissue-based evidence collection.
AI-powered prioritisation and triage
The pathologist’s time is the bottleneck in high-volume studies. Patholytix includes built-in AI tools to assist with triage, lesion detection, and study-wide pattern recognition. In partnership with top 10 Pharma, Patholytix is accelerating research through AI-supported screening and prioritisation. These tools help reviewers focus earlier on high-risk slides, reduce the review burden on normal tissue, and improve consistency across large datasets. The collaboration aims to bring AI into research workflows, both non-GLP and GLP studies, with regulatory-grade performance, a major advancement in study quality and efficiency.
These same AI models support discovery-phase applications, such as surfacing subtle tissue changes relevant to early target identification or detecting rare patterns across high-dimensional data cohorts.
Global scale, proven results
The acceleration benefits of Patholytix are not theoretical. They are already reshaping workflows across the global drug development landscape. In partnership with Charles River Laboratories, Patholytix now underpins a growing digital pathology infrastructure used across their non-clinical sites. Exclusively utilizing Patholytix’s Image Management capabilities, Charles River is streamlining study reviews, automating data capture, and enhancing collaboration between sites and sponsors.
Beyond non-clinical programmes, the platform is increasingly used to support biomarker development and translational alignment across discovery and development teams. Patholytix acts as the connective tissue between preclinical models and clinical strategy, enabling shared access to pathology insights at the point of decision.
Better science, delivered faster
Acceleration does not mean cutting corners. It means eliminating friction. With Patholytix, timelines compress not because teams work harder, but because the system works smarter. Manual handoffs are replaced with real-time transitions. Fragmented tools are consolidated into unified modules. Review becomes proactive, not reactive.
For pathologists, this means more time on science and less on logistics. For sponsors, it means faster access to results (without sacrificing rigour). For R&D leadership, it means studies stay on track (and on budget).
Conclusion
Research pathology is increasingly expected to deliver faster, more reproducible insights across diverse study types, from early exploratory models to late-stage regulatory studies. But progress is too often limited by the systems around the work: fragmented review tools, manual data handling, and limited ability to operationalise AI within compliant workflows.
Patholytix resolves these limitations by integrating image management, scoring, collaboration, and AI decision support into a single, structured platform. It reduces turnaround times, improves traceability, and enables high-quality, multi-reviewer studies to progress without unnecessary delays.
For teams under pressure to scale output, maintain consistency, and adapt to increasing complexity, Patholytix provides the infrastructure to deliver faster, more efficient research pathology at every stage of the pipeline.
Explore how Patholytix can accelerate your research.
Contact us or request a demo today.
Pharmaceutical R&D runs on precision, but speed is what separates discovery from delivery. Across research workflows, every delay, whether in slide review, data handoff, or peer concordance, compounds downstream impact. This typically results in missed milestones, strained budgets, and lost momentum in programmes that can’t afford to wait.
With Patholytix, study acceleration is no longer a by-product. It is a design principle.
More than just a digital pathology platform, Patholytix is purpose-built to accelerate the entire research pathology lifecycle. From primary review to peer collaboration, scoring to archiving, and AI-enabled decision support, the platform enables fewer manual handovers, faster insights, and real-time readiness across sites, teams, and regulatory use cases.
For pathologists, that means more time spent on science, less on coordination. For study directors and sponsors, it means faster access to structured results without compromising review quality. And for R&D leadership, it means studies stay on track, with clearer visibility, fewer delays, and less downstream rework.
Having managed millions of whole slide images across some of the world’s largest pharmaceutical programmes, we’ve built Patholytix to reflect how research actually happens, and to remove the friction that slows it down.
The Real Reasons Studies Stall
Even in organisations that have embraced digital review, pathology workflows often remain fragmented. Scanned slides are managed in one tool, findings in another. Sponsors request annotations by email. Metadata is corrected in Excel. Peer review (which should be collaborative) becomes a relay race of uploads and delays.
For studies that span thousands of slides across multiple reviewers, these inefficiencies become material. Review cycles stretch from weeks to months. Consensus becomes harder to track. Compliance adds friction. With increasing study complexity in areas like translational models and biologics, the cost of slowness continues to rise.
Delays can also be introduced at the point of slide digitisation. Studies can stall before review even begins due to scanning backlogs, inconsistent metadata capture, or manual triage processes that separate scanned images from study context. And while AI tools show promise for prioritisation and lesion detection, most teams struggle to deploy them in a way that aligns with internal research protocols, GLP expectations, and sponsor-specific requirements. Without infrastructure that supports both automation and traceability, AI remains disconnected from routine study execution.
Patholytix: An IMS designed for velocity
Patholytix addresses these pain points head-on by delivering an integrated digital pathology ecosystem designed for speed. At its core are three capabilities that collectively redefine what acceleration means in practice.
Real-time collaboration without handoffs
Patholytix enables full web-based peer review, where reviewers can comment, annotate, and build consensus directly within the same interface. There are no downloads, no version confusion, and no email threads. Observations from peer reviewers are automatically visible to primaries, audit-logged, and linked to specific slide regions. Whether the reviewers are across the hall or across continents, the study can progress in real time.
Integrated scoring and regulatory-ready reporting
Unlike platforms that stop at image viewing, Patholytix incorporates dedicated modules for data capture, scoring, and regulatory output. Pathologists can record findings as they review, with structured metadata and tagging, and generate tables and reports directly within the platform. This eliminates duplication, reduces errors, and saves days (or weeks) per study. All data is stored in a traceable, audit-ready format, ensuring nothing is lost in translation.
This functionality extends beyond preclinical workflows. For clinical trial support, Patholytix provides full traceability of image assessments used in biomarker validation, patient stratification, and tissue-based evidence collection.
AI-powered prioritisation and triage
The pathologist’s time is the bottleneck in high-volume studies. Patholytix includes built-in AI tools to assist with triage, lesion detection, and study-wide pattern recognition. In partnership with top 10 Pharma, Patholytix is accelerating research through AI-supported screening and prioritisation. These tools help reviewers focus earlier on high-risk slides, reduce the review burden on normal tissue, and improve consistency across large datasets. The collaboration aims to bring AI into research workflows, both non-GLP and GLP studies, with regulatory-grade performance, a major advancement in study quality and efficiency.
These same AI models support discovery-phase applications, such as surfacing subtle tissue changes relevant to early target identification or detecting rare patterns across high-dimensional data cohorts.
Global scale, proven results
The acceleration benefits of Patholytix are not theoretical. They are already reshaping workflows across the global drug development landscape. In partnership with Charles River Laboratories, Patholytix now underpins a growing digital pathology infrastructure used across their non-clinical sites. Exclusively utilizing Patholytix’s Image Management capabilities, Charles River is streamlining study reviews, automating data capture, and enhancing collaboration between sites and sponsors.
Beyond non-clinical programmes, the platform is increasingly used to support biomarker development and translational alignment across discovery and development teams. Patholytix acts as the connective tissue between preclinical models and clinical strategy, enabling shared access to pathology insights at the point of decision.
Better science, delivered faster
Acceleration does not mean cutting corners. It means eliminating friction. With Patholytix, timelines compress not because teams work harder, but because the system works smarter. Manual handoffs are replaced with real-time transitions. Fragmented tools are consolidated into unified modules. Review becomes proactive, not reactive.
For pathologists, this means more time on science and less on logistics. For sponsors, it means faster access to results (without sacrificing rigour). For R&D leadership, it means studies stay on track (and on budget).
Conclusion
Research pathology is increasingly expected to deliver faster, more reproducible insights across diverse study types, from early exploratory models to late-stage regulatory studies. But progress is too often limited by the systems around the work: fragmented review tools, manual data handling, and limited ability to operationalise AI within compliant workflows.
Patholytix resolves these limitations by integrating image management, scoring, collaboration, and AI decision support into a single, structured platform. It reduces turnaround times, improves traceability, and enables high-quality, multi-reviewer studies to progress without unnecessary delays.
For teams under pressure to scale output, maintain consistency, and adapt to increasing complexity, Patholytix provides the infrastructure to deliver faster, more efficient research pathology at every stage of the pipeline.
Explore how Patholytix can accelerate your research.
Contact us or request a demo today.
Follow us
Ireland
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin D11 KXN4
